Royalty Report: cardiac, Drugs, Therapeutic – Collection: 117698


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • cardiac
  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Surgical
  • Medical
  • Device
  • Drug Discovery
  • Technical Know How
  • Supply
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 117698

License Grant
The parties co-promote INTEGRILIN in the United States and share any profits or losses. Outside of the United States, the Swiss Licensee markets INTEGRILIN exclusively.

With this amendment the Parties desire to modify their agreement to address such issue of sales allocation, and also with respect to the allocation of regulatory responsibilities in Canada, the manufacture and supply of Integrilin Product in Canada, and to set forth certain understandings regarding a Phase III clinical trial for Integrilin Product in the setting of acute myocardial infarction or AMI.

License Property
INTEGRILIN(R) (eptifibatide) Injection, is the only drug approved for use in both acute coronary syndromes and angioplasty procedures.
Field of Use
This agreement is for the pharmaceutical industry.
INTEGRILIN is indicated for the treatment of patients with an acute coronary syndrome and patients who undergo angioplasty procedures. The acute coronary syndrome indication includes patients with unstable angina and non-Q-wave myocardial infarction, whether they receive medical treatment or undergo angioplasty.

Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.

Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.

IPSCIO Record ID: 3640

License Grant
The Company acquired the rights to Aggrastat® Injection (tirofiban hydrochloride) in the U.S. and itsterritories (Puerto Rico, Virgin Islands, and Guam).
License Property
Aggrastat®, a glycoprotein GP IIb/III a receptor antagonist, is used for the treatment of acute coronary syndrome (ACS) including unstable angina, which is characterized by chest pain when one is at rest, and non-Q-wave myocardial infarction (MI).  Aggrastat is a medicine which is used in prevention of a heart attack. Aggrastat contains tirofiban hydrochloride.
Field of Use
The Field of Use apply to the healthcare industry relating to the treatment of ACS.  Acute coronary syndrome (ACS) is usually one of three diseases involving the coronary arteries ST elevation myocardial infarction (30%), non ST elevation myocardial infarction (25%), or unstable angina (38%).

IPSCIO Record ID: 372578

License Grant
The original agreement between the Licensor of Sweden and Licensee is for selective inhibition ADP compound known as Cangrelor.

This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.

License Property
Cangrelor, a potent intravenous adenosine diphosphate-receptor antagonist, significantly reduced the rate of ischemic events, including stent thrombosis, during PCI without increasing severe bleeding when compared with clopidogrel, according to a late-breaking trial presented here.

CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.

Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.

Field of Use
The field of use is in patients undergoing percutaneous coronary intervention or PCI.  Cangrelor is used during percutaneous coronary intervention (PCI) for reducing the risk of heart attacks.  Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.

IPSCIO Record ID: 282942

License Grant
Licensee agrees to purchase from Belgian Licensor and Licensor agrees to manufacture and supply to Licensee an amount of Bulk Product through Purchase Orders.
License Property
Bulk Product shall mean a bulk peptide product which contains eptifibatide, is produced by the Licensed Process (as defined in the License Agreement) and is intended to undergo further processing, formulation and/or vialing and packaging.

Eptifibatide shall refer to a specific peptide designated by Licensee and known as eptifibatide, which same peptide was known previously as Integrilin or Integrelin, the chemical structure of which is known to Licensor because of the prior business relationship between Licensee and Licensor.

Field of Use
Eptifibatide (Integrilin) is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.

Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries).

IPSCIO Record ID: 203519

License Grant
The Parties previously entered a Collaboration Agreement provided Licensor the opportunity to participate in the development and commercialization of INTEGRILIN(R) (eptifibatide) Injection (INTEGRILIN).

The Parties wish to terminate Licensors role in the commercialization and manufacturing of INTEGRILIN in and for the Transferring Territory, and to have Licensors existing regulatory approvals and authorizations, contractual rights and responsibilities transferred in an appropriate manner to a new commercial licensee that this Licensee will identify.

This agreement, terminates certain License rights and modifies other certain license rights terms.  For the Modification of IP Licenses Granted to Licensee
– the exclusive licenses under the Licensor Patents granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN Products in the relevant country or countries or in the Transferring Territory, as applicable;
– the non-exclusive licenses under the Licensor Patents granted in the Collaboration Agreement with respect to the Manufacture of INTEGRILIN Products shall be exclusive, except as to Licensor and its Affiliates, with respect to the Manufacture of INTEGRILIN Products for distribution, use and/or sale in the relevant country or countries or in the Transferring Territory,
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement with respect to Manufacturing INTEGRILIN Products shall be exclusive, except as to Licensor solely with respect to Manufacturing INTEGRILIN Products in or for the relevant country or countries or in or for the Transferring Territory.

For Certain Copyrights and Trademarks, Licensor grants to Licensee and the New Commercial Licensee an exclusive, perpetual, sublicensable license under Licensors copyrights in all Marketing Materials solely for use in Commercializing INTEGRILIN Products in the Transferring Territory.

License Property
INTEGRILIN(R) (eptifibatide) Injection (INTEGRILIN), is a small peptide pharmaceutical.  INTEGRILIN prevents blood clots or heart attack in people with severe chest pain and in patients undergoing angioplasty.

The Trademark means all registrations, applications for registration and other rights in and to the INTEGRILIN mark and the APEREXIN back-up mark for the Development, Manufacture and Commercialization of INTEGRILIN Products in or for the Transferring Territory.

The New Commercial Agreement means a definitive agreement between Licensee and a Pharmaceutical Company under which such Pharmaceutical Company is granted a license to INTEGRILIN Products and assumes primary responsibility for the Development and Commercialization of the INTEGRILIN Products in and for the Transferring Territory, and the Manufacture of the INTEGRILIN Products for Development and Commercialization in the Transferring Territory.

Field of Use
The Field means the treatment, prevention and/or control of cardiovascular diseases and conditions in humans.

IPSCIO Record ID: 328338

License Grant
Licensor grants the Licensee of Japan the right and license, with no right to sublicense except as provided under the Licensor Patents and the Know-How, solely to use the Licensed Compounds to conduct Development and to import, use, and sell Products solely for use in the Field within the Territory.

For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.

For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.

The Parties are to develop  and  commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel  following an angioplasty or similar procedure,  and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.

License Property
Licensor is engaged in research and  development of, among other things, oligonucleotides and oligonucleotide  analogs that may be useful for therapeutic treatment of disease conditions.   Licensor is presently developing  one such oligonucleotide compound, identified as LR-3280 targeted to c-myc mRNA, as a pharmaceutical product for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure.

The patents subject matter includes but is not limited to
–  Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
–  Method of treating restenosis by administrating c-myr antisense;
–  Method of Inhibiting collagen synthesis by treating with c-myr antisense;
–  Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
–  Pharmaceutical compositions for the above methods.

Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.

Clinical Trial Product means a product,  appropriate for use in clinical trials, containing a Licensed  Compound or placebo, as applicable, in the formulation as determined by Licensee.

Field of Use
Field means the prevention or treatment of restenosis in humans in any blood vessel by use of a Licensed Compound delivered to the affected blood vessel via a Delivery Means following any stenosis-reducing medical procedure that is Transient in nature and that is intended to reduce the obstruction of the blood flow in a stenosed vessel (including without limitation percutaneous transluminal angioplasty, percutaneous transluminal coronary angioplasty and angioplasty involving placement of an intravascular stent).

Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.

IPSCIO Record ID: 255948

License Grant
This Agreement is for the Transfer and assign from Licensor to Licensee for all right, title, and interest to the patent and related clinical information covering LiprostinTM.
License Property
The pharmaceutical drug candidate is LiprostinTM for improving the effectiveness of current standard-of-care treatments related to endovascular interventions in the treatment of peripheral artery disease (PAD). LiprostinTM has completed FDA Phase I and three Phase II clinical trials, and we are evaluating several contract research organizations ('CRO') for completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase III.
Field of Use
The clinical stage patented pharmaceutical brand LiprostinTM is focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).
Peripheral artery disease is a narrowing of the peripheral arteries serving the legs, stomach, arms and head. (“Peripheral” in this case means away from the heart, in the outer regions of the body.) PAD most commonly affects arteries in the legs. Both PAD and coronary artery disease (CAD) are caused by atherosclerosis.

IPSCIO Record ID: 28285

License Grant
Under the terms of our 2008 Revenue Sharing Agreement with the Licensee, Licensor retains all revenue from the sale of a product commercialized under a 505(b)(2) application until we have recouped our expenses related to the development of that product.
License Property
Argatroban is a Prescription Drug used to treat or prevent blood clots in patients with bleeding problems caused by another medicine called heparin. Also given to patients before having balloon angioplasty, a procedure to open a clogged artery.
Field of Use
Bivalirudin is a Prescription that prevents blood clots during a heart procedure called angioplasty. This medicine is used with aspirin.

IPSCIO Record ID: 27406

License Grant
The Company, in its acquisition of technology in 1993 related to its TMR therapy from the University.  Under this agreement, the Company has a worldwide exclusive license to any patents that issue in connection related with cardiac revascularization technology for the treatment of advanced cardiovascular disease and severe angina pain through transmyocardial revascularization, TMR.
License Property
TMR is a treatment aimed at improving blood flow to areas of the heart that were not treated by angioplasty or surgery. A special carbon dioxide (CO2) laser is used to create small channels in the heart muscle, improving blood flow in the heart. TMR is a surgical procedure. The procedure is performed through a small left chest incision or through a midline incision. Frequently, it is performed with coronary artery bypass surgery, but occasionally it is performed independently.
Field of Use
Field of use  Medical Industry primarily used by a heart surgeon.

IPSCIO Record ID: 352721

License Grant
This agreement is to develop a new manufacturing process, the Chemilog process, of the active pharmaceutical ingredient Bivalirudin.

In order to establish Licensor/Manufacturer of Belgium as a preferred supplier of the Product on a commercial basis, Manufacturer shall perform the development and manufacture of the Product in its premises in Belgium according to the terms.

License Property
The Manufacturer has suitable premises, equipment and expertise in the development and production of pharmaceutical grade bulk peptides.

Manufacturer Technical Information shall mean
– unpatented proprietary and confidential technical information, specifications, compositions, manufacturing methods, application methods, testing methods, computer programs,technical data and drawing as well as any improvements thereto.
– patents and patent applications on any of the foregoing, including divisions, owned by, or licensed or assigned to Manufacturer, and based on inventions which are either actually reduced to practice or constructively reduced to practice by filing a patent application on such invention prior to the termination of this Agreement, continuations, continuations in part, extensions, amendments and reissues thereof.

Bivalirudin shall mean the 20 amino acid polypeptide corresponding to LC13 Code Name SP071 and/or SF220.

Chemilog shall mean the process by which Bivalirudin API is manufactured.

Product shall mean the fully chemically synthetized Bivalirudin API either through Manufacturers existing process or the Chemilog Process.

Licensor manufactured two validation batches of Angiomax bulk drug substance using the Chemilog proces.

Angiomax directly blocks or inhibits the actions of thrombin, a key component in
the formation and growth of blood clots.

Field of Use
Licensee/Buyer has acquired certain rights to the synthetic drug substance Bivalirudin
(Angiomax(R)) and is developing and marketing pharmaceutical compositions containing Bivalirudin for the treatment of PTCA and other diseases.  

Angiomax is for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty.

Angiomax has
      –     reduced the frequency of life-threatening coronary events including heart attack and the need for emergency coronary procedures;

      –     reduced the likelihood of major bleeding and the need for blood transfusion;

      –     demonstrated a predictable anticoagulant response to a specific Angiomax dose, which enables simplified dosing; and

      –     been used in combination with GP IIb/IIIa inhibitors and other products used in angioplasty

IPSCIO Record ID: 8745

License Grant
Licensee signed an agreement with Japanese Licensor pertaining to the development and commercialization of adenosine for use in the treatment of acute ischaemic conditions of the heart, including acute myocardial infarction and open-heart surgery (formerly designated MEDR 640 programs) in the US and Canada.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 28946

License Grant
The Israel Licensors hereby grants to the Licensee the exclusive, royalty-bearing right and license in the Territory under the Licensee's Intellectual Property (including, for clarity, a sublicense under the Sublicensed IP) to Develop, Manufacture and Commercialize Products for use in the Field.
License Property
The Licensor owns or controls certain intellectual property rights covering a liquid polymer composed of Sodium Alginate and Ca-D-Gluconate (designated by BioLineRx as “BL-1040”).  The Licensor is currently developing the Product (as defined below) as a medical device for the direct treatment of cardiac tissue following acute myocardial infarction.

Bioabsorbable cardiac matrix, or BCM, is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union.

BCM is a medical device intended to prevent congestive heart failure following a STEMI, which is a type of severe heart attack.

BCM is delivered during a minimally invasive, commonly performed cardiac procedure called a percutaneous coronary intervention procedure. BCM is a formulated sterile solution of sodium alginate and calcium gluconate designed to be administered as a liquid through the coronary artery. When administered following a STEMI, BCM flows into damaged heart muscle where, in the presence of abnormally high extracellular calcium released by the damaged cells, it forms a protective hydrogel meshwork within the wall of the heart’s left ventricle. Based on pre-clinical animal studies, we believe that BCM has the potential to act as a flexible scaffold to provide physical support to the ventricle wall in the early stages of recovery following a STEMI and prevent further structural damage while the heart muscle heals. In addition, in our pre-clinical animal studies, as calcium levels in the damaged area returned to normal, BCM dissolved and was excreted through normal kidney function.

Field of Use
The Licensee is developing BCM for the prevention of cardiac remodeling, which often leads to congestive heart failure following an ST-segment elevated myocardial infarction, or STEMI.

IPSCIO Record ID: 368507

License Grant
The Licensor, an individual, hereby grants to Licensee an exclusive license to practice under the Licensed Patents and use the licensed information, with the right to grant sublicenses, to make, have made, use, sell, have sold, offer to sell, import or export Licensed Products within the field in the licensed territory (the License).
License Property
The intellectual property portfolio for 2NTX-99 includes an issued U.S. patent and a pending Patent Cooperative Treaty submission relating to its composition of matter, multiple methods of manufacturing, and method of use in treating a variety of atheroclerotic-thrombotic pathological conditions.

U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.

Field of Use
2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.

Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).

IPSCIO Record ID: 26864

License Grant
University is willing to grant a worldwide, exclusive license in the defined FIELD OF USE to Licensee.  The University is the owner and that it has the right to exclusively license those inventions which are the subject matter of USC File No. 2651 entitled 'Balloon Protection Guide Wire Device For Carotid Balloon Angioplasty and Stenting' and USC Pile 2639 entitled 'New Balloon-Inflated Carotid Artery Stent to Assist in Carotid Artery Balloon Angioplasty'.
License Property
Guardian Embolization Protection System patented technology with primary use in the neurointerventional and cardiology markets these markets focus on arteries and veins leading to the brain and those in the heart, and the removal of blockages in these veins and arteries.  The device is designed to prevent deadly embolisms during surgery to clear blocked arteries and prevent strokes and heart attacks.  The key to this device, known as the Guardian System, is a thin string of wire, really a metal tube not much larger in diameter than a human hair, with a marble-sized balloon attached toward the end.

USC File 2651 U.S. Patent Application Serial No. 08/767,221 filed December 16, 1996 (abandoned) entitled 'Cerebral Protection Balloon For Use In Carotid Artery Angioplasty and Stenting'

USC File 2561 U.S. Patent Application Serial No. 08/906,890 filed August 6,1997 (which is a continuation of U.S. Ser. No. 08/767,221), entitled Angioplasty Catheter'.

USC File 2561 PCT Patent Application Serial No. PCT/US97/23257 filed December16, 1997 and corresponding to U.S. Patent Applications Serial Nos. 08/767,221and 08/906,890.

USC File 2639 Invention Disclosure entitled 'New Balloon-Inflated Carotid Artery Stent to Assist in Carotid Artery Balloon Angioplasty'.

Field of Use
'FIELD OF USE' shall mean diagnostic and/or therapeutic devices to be used in the treatment or management of patients via the carotid artery or other arteries or veins.

IPSCIO Record ID: 27250

License Grant
The Company granted an exclusive license to manufacture and market Adenocard in the United States and Canada.  Adenocard(R) – a sterile formulation of adenosine for injection indicated for the  treatment of abnormally rapid heartbeats originating in the upper chambers of the heart, so-called paroxysmal supraventricular tachycardia.
License Property
Adenoscan is a sterile formulation of adenosine (3mg/ml) available in 30ml or 20ml vials for infusion indicated as an adjunct to thallium cardiac imaging in the evaluation of coronary artery disease.  Adenoscan is used by doctors to help diagnose heart disease.  The drug is used by doctors to simulate stress for elderly patients and others who cannot exercise on a treadmill.  In October 1988, the Company completed clinical trial and received FDA approval to market Adenocard in the United States.
Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.